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Abstract
Background: Several lines of evidence indicate that memory loss represents a synaptic failure caused by soluble
amyloid b (Ab) oligomers. However, the pathological relevance of Ab oligomers (AbOs) as the trigger of synaptic
or neuronal degeneration, and the possible mechanism underlying the neurotoxic action of endogenous AbOs
remain to be determined.
Results: To specifically target toxic AbOs in vivo, monoclonal antibodies (1A9 and 2C3) specific to them were
generated using a novel design method. 1A9 and 2C3 specifically recognize soluble AbOs larger than 35-mers and
pentamers on Blue native polyacrylamide gel electrophoresis, respectively. Biophysical and structural analysis by
atomic force microscopy (AFM) revealed that neurotoxic 1A9 and 2C3 oligomeric conformers displayed non-fibrilar,
relatively spherical structure. Of note, such AbOs were taken up by neuroblastoma (SH-SY5Y) cell, resulted in
neuronal death. In humans, immunohistochemical analysis employing 1A9 or 2C3 revealed that 1A9 and 2C3 stain
intraneuronal granules accumulated in the perikaryon of pyramidal neurons and some diffuse plaques. Fluoro Jade-
B binding assay also revealed 1A9- or 2C3-stained neurons, indicating their impending degeneration. In a long-
term low-dose prophylactic trial using active 1A9 or 2C3 antibody, we found that passive immunization protected
a mouse model of Alzheimer’s disease (AD) from memory deficits, synaptic degeneration, promotion of
intraneuronal AbOs, and neuronal degeneration. Because the primary antitoxic action of 1A9 and 2C3 occurs
outside neurons, our results suggest that extracellular AbOs initiate the AD toxic process and intraneuronal AbOs
may worsen neuronal degeneration and memory loss.
Conclusion: Now, we have evidence that HMW-AbOs are among the earliest manifestation of the AD toxic
process in mice and humans. We are certain that our studies move us closer to our goal of finding a therapeutic
target and/or confirming the relevance of our therapeutic strategy.
Background
Alzheimer’s disease (AD) represents the so-called “storage
disorder” of amyloid b (Ab). The AD brain contains solu-
b l ea n di n s o l u b l eA b, both of which have been hypothe-
sized to underlie the development of cognitive deficits or
dementia [1-3]. The steady-state level of Ab is controlled
by the generation of Ab from its precursor, the degrada-
tion of Ab within the brain, and transport of Ab out of the
brain. The imbalance among three metabolic pathways
results in excessive accumulation and deposition of Ab in
the brain, which may trigger a complex downstream cas-
cade (e.g., primary amyloid plaque formation or secondary
tauopathy and neurodegeneration) leading to memory loss
or dementia in AD. Accumulated lines of evidence indi-
cate that such a memory loss represents a synaptic failure
caused directly by soluble Ab oligomers (AbOs) [4-6],
whereas amyloid fibrils may cause neuronal injury indir-
ectly via microglial activation [7]. Thus, the classical
amyloid cascade hypothesis [8] underwent a modification
in which the emphasis is switched to the intermediate
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[7]. If this were the case, therapeutic intervention targeting
AbOs may be effective in blocking this pathogenic cas-
cade. The outcome of a recent human AN-1791 trial con-
firmed that plaque removal did not prevent the
progression of neuronal degeneration [13], supporting this
hypothesis.
However, the distinct assembly states of AbOs remain
to be elucidated. Several forms of AbOs have been
found to be neurotoxic, from LMW-oligomers (dimers,
trimers, and tetramers) disrupting memory function
[14,15], synaptic function [15,16] and long-term poten-
tiation (LTP) [14,17], to dodecamers affecting memory
[18]. In addition, Ab-derived diffusible ligands (or
ADDLs) [9,19], globulomers [11], fibrillar Ab oligomers
[20,21], and toxic soluble Ab assembly (TAb) [22] have
been shown to be highly synaptotoxic or neurotoxic.
Recently, a particular form of AbO, named the native
amylospheroids [23], has been isolated from AD brains
and found to induce neuronal loss through its binding
to synaptic targets [24].
In this study, we chose a prophylactic passive immuniza-
tion as a tool to define not only the pathological relevance
of AbOs as the trigger of synaptic or neuronal degenera-
tion, but also the possible mechanism underlying the neu-
rotoxic action of endogenous AbOs. To address this issue,
we successfully generated monoclonal 1A9 and 2C3 anti-
bodies using a novel design method. When extracellular
high-molecular-weight (HMW)-AbOs were controlled by
1A9 or 2C3 in Swedish-type amyloid precursor protein
(APP) transgenic mice (Tg2576), we demonstrated that
synaptic/neuronal degeneration or accumulation of intra-
neuronal AbOs was effectively prevented. These results
argue for a role of both extracellular and intracellular
HMW-AbOs in the induction and progression of synaptic
or neuronal degeneration and provide a potential explana-
tion for the extracellular one as the primary molecular
basis for a toxic process.
Results
Generation of Ab oligomer-specific monoclonal
antibodies
Since the removal of AbMs is critical for the preparation
of antigens to obtain AbO-specific antibodies, we iso-
lated SDS-stable Ab tetramers alone without any con-
tamination of Ab trimers and AbMs by SDS-PAGE
(Figure 1A). After in vivo immunization with the gel
containing the Ab tetramer alone, positive hybridoma
supernatants were screened by dot blot analysis. Among
positive supernatants (16/400, positive % = 4%), two
clones, namely, 1A9 and 2C3, were generated from a
mouse that produced IgG2b. As shown by dot blot ana-
lysis, both 1A9 and 2C3 recognized soluble AbOs
(100,000 g supernatant (sup) of 4-h-incubated mixture,
Figure 1B and 1C), not AbMs (560,000 g sup of seed-
free preparation, Figure 1B) or Ab fibrils (100,000 g pel-
let of 120-h-incubated mixture, Figure 1C), in contrast
with 4G8 (Figure 1B and 1C). The generation of A11-
or 2C3-immunoreactive oligomers preceded that of
1A9-immunoreactive oligomers (Figure 1B). The 1A9
conformer displayed a different pattern of its time
course, showing the highest stability in the oligomeric
assembly state (Figure 1B).
We further assessed the precise size of 1A9- or 2C3-
immunoreactive AbOs. Blue native polyacrylamide gel
electrophoresis (BN-PAGE), a charge shift method of elec-
trophoresis, was carried out to determine the molecular
mass and native oligomeric status of the 4-h-incubated
m i x t u r e .A ss h o w ni nF i g u r e1 D ,t h en a t i v eA b species
exhibit Ab monomers, low-molecular-weight (LMW)-
oligomers (dimers, trimers, tetramers, pentamers, and hep-
tamers), and a high-molecular-weight (HMW)-oligomeric
smear with molecular masses ranging in sizes from 66 to
720 kDa (Figure 1D). Immunoblot analysis employing
monoclonal 1A9 revealed its immunoreactivity with Ab
species corresponding to HMW-oligomeric smear of 480
to 1048 kDa (Figure 1E), whereas 2C3 immunoreacted
with Ab species corresponding to a broad smear of 146 to
1048 kDa plus minute amounts of pentamers (Figure 1E).
The anti-oligo A11 immunoreacted with native Ab species
corresponding to a HMW-smear ranging in sizes from
242 to 1000 kDa (Figure 1E), whereas monoclonal 4G8
detected Ab oligomers larger than tetramers (Figure 1E).
The combination of two-dimensional native/SDS-PAGE
and 4G8-immunoblot analysis revealed that 2% SDS disag-
gregates HMW-AbOs down to monomers and LMW-
oligomers in addition to SDS-stable HMW-oligomers with
molecular masses corresponding to those of 8~40-mers
(Figure 1F). These findings suggest that the assignment of
oligomer size is dependent on the method of evaluation.
Indeed, monoclonal 4G8 detected all the Ab species sepa-
rated, whereas anti-oligo A11, 1A9, or 2C3 immunor-
eacted with SDS-stable 15-mers to 40-mers under our
denaturing conditions tested (Figure 1G), indicating that
1A9 or 2C3 is indeed specific to AbOs.
Characterization of neurotoxic AbOs
We further assessed the morphology of neurotoxic AbOs.
After 0-h-, 2-h- or 4-h-incubation at 37°C, we tested the
bioactivity of each incubated mixture (25 μM) by incu-
bating NGF-differentiated PC12 (PC12N) cells [22] at
37°C for 48 h. Surprisingly, Live/Dead two-color fluores-
cence assay [22] revealed that 2-h- or 4-h-preformed
Ab42 assembly decreased the toxic activity, whereas
depletion of “insoluble” AbOs and concentration of
“soluble” AbOs fully restored the toxic activity, similarly
to that of Ab42 assembly formed from seed-free fresh
peptide (0 h) (Figure 2A). These data indicated that
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Figure 1 Generation and characterization of oligomer-specific antibody. (A) Electrophoresis of immunogen. SDS-PAGE was performed to
isolate the Ab1-42 tetramer (red closed arrowhead) alone without any contamination by the Ab1-42 trimer (black closed arrowhead) and Ab1-42
monomer (opened arrowhead). Lane 1, Ab1-42 dissolved in 10 mM phosphate buffer; lane 2, Ab1-42 dissolved in distilled deionized water. (B)
Ab1-42 oligomer formation was observed as a function of time. Ab1-42 monomer (25 μM) incubated at 37°C for the indicated time (0 - 72 h)
were spotted on nitrocellulose membrane and subjected to a dot blot assay using A11 (1:100), 1A9 (1:50), 2C3 (1:50), or 4G8 (1:1000). (C) In this
dot blot assay (left half of panel C), 1 μg of soluble Ab42 oligomers (100,000 g sup for 4-h-incubation at 37°C) and Ab42 fibrils (100,000 g pellets
for 120-h-incubation at RT) were applied on a nitrocellulose membrane and probed with A11, 1A9, 2C3, or 4G8. EM image of fibrils (right half of
panel C). (D) Characterization of Ab1-42 oligomers under nondenaturing conditions. Ab1-42 monomer (25 μM) incubated at 37°C for 4 h was
separated on 16% BN-PAGE. (E) Separated peptides under nondenaturing conditions were also subjected to immunoblot analysis using A11, 1A9,
2C3, and 4G8. (F) The 100000 g sup of 4-h-incubated mixture of Ab1-42 monomer (25 μM) was subjected to two-dimensional native/SDS-PAGE,
followed by 4G8-immunoblot analysis. SDS-stable 15~40-mers are indicated (] (red)). (G) Immunodetection of 4-h-incubated mixture of Ab1-42
monomer (25 μM) under denaturing conditions probed with A11, 1A9, 2C3, and 4G8. SDS-stable 15~40-mers are indicated (] red).
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Page 3 of 16Figure 2 Biophysical and structural characterization of neurotoxic Ab assembly. (Upper half of panel A) Representative calcein AM/PI
stainings of NGF-treated PC12 (PC12N) cells treated at 37°C for 48 h with: TBS alone; 0-h preincubated Ab1-42 (0 h); 2-h preincubated Ab1-42 (2
h); 540,000 g supernatant obtained from 2 h (2 h sup); 4-h preincubated Ab1-42 (4 h); 540,000 g supernatant obtained from 2 h (4 h sup). Green
staining for viable cells versus red staining for dead cells. Resultant cell viability for each treatment is shown in lower half of panel A.
Experimental results were analyzed by one-way ANOVA, followed by Tukey’s test for posthoc analysis: statistical significance compared with TBS
alone (*p<0.0001). Scale bar = 50 μm. (B) The seed-free Ab1-42 (25 μM) was subjected to a series of membrane ultrafiltration steps with
molecular cutoffs at 3, 10, 30, and 100 kDa. The resultant four filtrates and one retentate were designated as Fr. 1 (<3 kDa), Fr. 2 (3-10 kDa), Fr. 3
(10-30 kDa), and Fr. 4 (30-100 kDa), and final retentate Fr. 5 (>100 kDa). The upper half of panel B shows the representative calcein AM/PI
stainings of NGF-treated PC12 (PC12N) cells incubated at 37°C for 48 h with seed-free unfractionated Ab1-42 or five fractions (25 μM each).
Resultant cell viability for each treatment is shown in the lower half of panel B. Experimental results were analyzed by one-way ANOVA, followed
by Dannett’s test for posthoc analysis: statistical significance compared with TBS alone (*p<0.001). (C) Dot blot analysis of five fractions (Frs. 1-5).
The blots were reacted with A11, 1A9, 2C3, and 4G8. (D) Amplitude AFM images (2 μm×2μm) of four fractions (Frs. 2-5). All AFM images were
taken on a mica surface.
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Page 4 of 16seed-free fresh peptide (0 h) is the best source of de novo
formation of neurotoxic AbOs. We isolated soluble Ab
species originated from seed-free fresh peptide by ultra-
filtration and molecular sieving, which allowed us to
separate the toxic Ab42 peptide into five fractions (Figure
2B). To verify the size distribution of toxic Ab42, PC12N
cells were exposed to each fraction (25 μM) at 37°C for
48 h (Figure 2B). The level of LDH released from PC12N
cells, when treated with each fraction, was similar to that
treated with TBS alone. Live/Dead two-color fluores-
cence assay [22] revealed the toxicity of unfractionated
Ab42 or Frs. 3-5 (Figure 2B, F (6/77) = 39.85, p <
0.0001), suggesting that toxic oligomers are at least larges
trimers. Neurotoxic AbOs were then subjected to further
dot blot immunoanalysis without SDS to determine their
size, in which their “native” conformations are supposed
to be maintained (Figure 2C). Monoclonal 4G8 detected
Ab species in Frs. 2-5. The anti-oligomer A11 unequivo-
cally reacted with toxic oligomeric conformers in Frs.
3-5. In contrast, 2C3 immunoreactivities were observed
in Frs. 4 and 5, whereas minute amounts of 1A9 confor-
mers were detected in toxic Fr. 5 alone. Taken together,
these data suggest that both 1A9 and 2C3 toxic confor-
mers are larger than 100 kDa and 30 kDa, respectively.
Atomic force microscopy (AFM) [25] of toxic fractions
revealed structures of different sizes and morphologies,
including relatively compact spherical particles approxi-
mately 5-10 nm in diameter, large spherical particles
roughly 25-50 nm in diameter, and an annular pore like
structure 25 nm in inner and 75 nm in outer diameters
(Figure 2D).
1A9 and 2C3 immunoreactivitiy in human tissue
To investigate the distribution of 1A9 and 2C3 staining in
human tissue, immunohistochemistry was performed on
brain tissues obtained from 4 AD and 3 age-matched nor-
mal cases. The use of monoclonal 1A9 (Figures 3A and 3I)
and, to a lesser extent, monoclonal 2C3 (Figures 3B and 3J)
and polyclonal A11 (Figures 3C and 3K) revealed that
AbOs are highly localized within pyramidal neurons.
Within these cells, AbOs accumulated as densely packed
granules in the perikarya (Figures 3A-C). Some of the dif-
fuse plaques were stained by 1A9, but diffuse deposits were
poorly stained by 2C3 and A11 (Figures 3A-C). The major-
ity of 1A9-stained pyramidal neurons exhibited atypical,
eccentric large nuclei with abnormal chromatin morphol-
ogy and distributions, features indicative of impending neu-
ronal degeneration (Figures 3A and 3I). Such abnormalities
were less evident in 2C3- or A11-stained pyramidal
neurons (Figures 3B, C, J and 3K). Although age-matched
control brains sometimes contained isolated clusters of
AbO-burned neurons (Figures 3D), the number of neurons
involved and the amount of AbOs accumulated within
these cells were much lower than those in AD brains
(Figures 3D and 3I). Typically, 1A9-immunoreactive gran-
ules in control brains were relatively small, numerous, and
rather uniformly distributed throughout the perikaryon of
pyramidal neurons and the proximal portion of apical den-
drites (Figure 3D). In addition, intraneuronal AbOs were
diffusely distributed throughout the perikaryon of pyrami-
dal neurons, which appears to be a characteristic feature
in control brains (Figures 3E and 3I-K). In AD brains,
intraneuronal AbOs were sequestered into large, densely
packed aggregates in the dendritic trunk and/or branches,
and axons (Figures 3A-C). Interestingly, some showed
multiple dot-like accumulation of 1A9-immunoreactive
AbOs arranged in tandem along apical dendritic shafts,
which were focally swollen with an accumulation of 1A9-
immunoreactive AbOs (Figure 3F). The presence of intra-
neuronal Ab was further supported by the staining by the
widely used 4G8 (Figure 3G) and 6E10 (Figure 3H).
Extracellular AbOs are uptaken by neurons
To gain further insight into the link between extracellu-
lar and intraneuronal AbOs, neuroblastoma (SH-SY5Y)
cells were incubated with 5μM HiLyte Fluor™488-
labeled AbMs, AbOs, or Fluor™488 alone. Immunocy-
tochemical analysis showed that fluorescence-labeled
AbOs, not AbMs, bind to neuronal membrane for
10 min, followed by accumulation of intraneuronal
AbOs for 0.5 or 3 hr (Figure 4A). Vesicular uptake was
not observed with fluorescence alone (Figure 4A). Only
when Fluor™488-labeled AbOs were added to SH-SY5Y
cells, the LDH release assay [22] of cultures of SH-SY5Y
cells revealed that the level of released LDH increased
as a function of time (Figure 4B), suggesting that accu-
mulation of intraneuronal AbOs induces neuronal cell
death. The cell death was not detectable in the case of
synthetic Ab 42-1 and AbMs (Figure 4B).
Monoclonal 1A9 or 2C3 immunotherapy protects Tg2576
from memory impairment
Using active 1A9 and 2C3 antibodies, we next evaluated
whether a specific control of endogenous AbOs in vivo
would be sufficient to prevent the disruption of neuronal
function leading to memory loss. To assess this possibility,
a long-term low-dose prophylactic study using 1A9 and
2C3 was designed instead of a therapeutic approach that
was used previously by other scientists [26,27]. Tg2576
mice were injected with 2C3 (n = 12), 1A9 (n = 13), or PBS
(n = 10) into the tail vein (0.4 mg/kg/week) from 4 months
of age (that is, about 2 months before the onset of memory
loss) until 13 months of age (when memory loss and amy-
loid plaque formation are already well established). Mem-
ory functions were measured in four behavioral paradigms,
as described previously [28]: (1) short-term memory in the
Y-maze test (Figure 5A); (2) object recognition memory in
a novel object recognition te s t( F i g u r e5 B ) ;( 3 )s p a t i a l
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Page 5 of 16memory in the water maze test (Figures 5C); and (4) asso-
ciated emotional memory in the contextual fear learning
test (Figures 5D and 5E). Untreated Tg2576 mice (n = 14)
showed a significantly poorer behavioral performance than
untreated wild-type mice in all the behavioral paradigms
tested (Figure 5A-5E). Tg2576 mice treated with 1A9 and,
to a lesser extent, 2C3 showed significantly better beha-
vioral performance than untreated Tg2576 mice in all the
behavioral paradigms tested (Figures 5A-5E). Unlike that
of untreated Tg2576 mice, the performance of 1A9- or
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Figure 3 Immunolabelling characteristics of 1A9, 2C3, A11, 6E10 and 4G8 in human brains. Typical AbO immunolabelling is observed in diffuse
plaques (arrow) and the perikaryon of pyramidal neurons (arrow head) as dense granules (A and C) or diffuse staining (B) in AD brains (400X): 1A9
(1:50, panel A), 2C3 (1:50, panel B), and A11 (1:250, panel C). In control brains (D), 1A9 disclosed small granular intraneuronal staining in isolated clusters
of pyramidal neurons (400X). (E) Diffuse intraneuronal staing is a characteric feature of control brains (A11, 1:250; 400X). (F) 1A9-positive granules were
often observed in dendrires (⊔) in AD brains (400X). (G-H) 4G8 (1:100) and 6E10 (1:100) immunoreactivities were also observed in neurons (arrow head)
and diffuse plaques (arrow) of AD brains, respectively (400X). (I-K) Determinations of number of intraneuronal AbO immunolabelling in human brains:
1A9 (panel I), 2C3 (panel J), and A11 (panel K). Designations used herein were as follows: Granular, dense granule staining; Diffuse, diffuse staining;
None, no staining; NC, normal control; AD, Alzheimer’s disease. Experimental results of staining pattern were analyzed by one-way ANOVA, followed by
Dannett’s test for posthoc analysis: statistical significance compared with NC (*p < 0.01, **p < 0.001).
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Page 6 of 162C3-treated Tg2576 mice was indistinguishable from that
of untreated wild-type mice (n = 14) that had been pre-
viously tested in these tasks at this age [28], indicating that
both short-term and long-term memories were well pre-
served in 1A9- or 2C3-treated Tg2576 mice.
Monoclonal 1A9 or 2C3 immunotherapy protects Tg2576
from synaptic degeneration and neuronal degeneration
The synaptoprotective effect was also confirmed at the
postsynapse level, not at the presynapse level, at which
the relative intensities of PSD-95 (Figure 6A) to actin
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Figure 4 Cell uptake of neurotoxic AbOs. (A) SH-SY5Y cells were exposed to Fluor™488 alone, 5 μM HiLyte Fluor™488-labeled AbMs or AbOs
(green) at 37°C for 10, 30, and 180 min. AbMs: 10 kDa-filtrate; AbOs:30 kDa-retentate. Nuclear staining (7-AAD) is shown in red. Vesicular uptake
was observed with AbOs, but not with AbMs and Fluor™488 alone. (B) The level of LDH released from SH-SY5Y cells treated for the indicated
times (0, 3, 6, and 24 h) with 5 μMA bOs. In the case of 5 μM synthetic Ab42-1 and AbMs, LDH assay was done for 24 h. Each value indicates
the percentage level of LDH released following treatment with incubation mixtures relative to the level of LDH released following treatment
with Triton X-100. Each column indicates average ± S.D. The p value was determined by one-way ANOVA, followed by Dannett’s test for
posthoc analysis: statistical significance compared with AbMs alone (*p < 0.05, **p < 0.001).
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Figure 5 Passive immunization protects Tg2576 mice from memory deficits. Tg2576 mice at 13 months of age in three groups were
studied: PBS-treated non-Tg mice, n = 14; PBS-treated Tg2576 mice, n = 10; 1A9-treated mice, n = 13; 2C3-treated mice, n = 12. Values indicate
the mean ± SEM. (A) Y-maze test. Spontaneous alternation behavior during an 8-min session in the Y-maze task was measured in each group.
Results of one-way ANOVA were as follows: F(3, 45) = 2.99, p < 0.05, **p < 0.05 vs PBS-treated non-Tg mice, #p < 0.05 vs PBS-treated Tg2576
mice. (B) Novel object recognition test. The retention session was carried out 24 h after the training. Exploratory preference during a 10-min
session in the novel-object recognition test was measured in each group. Results of the two-way ANOVA were as follows: training/retention, F
(1, 90) = 58.19, p < 0.01; animal group, F(3, 90) = 6.18, p < 0.01; interation of training/retention with animal group, F(3, 90) = 7.57, p < 0.01;
**p < 0.01 vs corresponding trained mice. ##p < 0.01 vs PBS-treated non-Tg mice, **p < 0.01 vs PBS-treated Tg2576 mice. (C) Swimming-path
length during a 60-s session in the water maze test was measured in each group. Results of the two-way ANOVA were as follows: trial, F(9, 450)
= 25.51, p < 0.01; animal group, F(3, 450) = 14.85, p < 0.01; interaction of trial with animal group, F(27, 450) = 1.36, p = 0.11; **p < 0.01 vs
PBS-treated non-Tg mice, #p < 0.05, ##p < 0.01 vs PBS-treated Tg2576 mice. Conditioned fear learning test: context-dependent (D) and cue-
dependent (E) freezing times were measured. The results of one-way ANOVA were as follows: context-dependent test, F(3, 45) = 6.19, p < 0.01;
cue-dependent test, F(3, 45) = 5.41, *p < 0.05; **p < 0.01 vs PBS-treated non-Tg mice, #p < 0.05, ##p < 0.01 vs PBS-treated Tg2576 mice.
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Page 8 of 16were significantly higher in 2C3-treated Tg2576 mice
than in untreated Tg2576 mice. This is not the case
with synaptophysin (Figure 6A). Thus, 2C3 indeed pro-
tect Tg2576 mice from postsynaptic degeneration. In
addition, the intensities of drebrin (Figure 6A) relative
to those of actin were significantly higher in 1A9-treated
Tg2576 mice, indicating that 1A9 protects Tg2576 mice
from the degeneration of dendritic spines. This assump-
tion was further supported by image analysis of synapto-
physin, PSD-95, or drebrin after immunofluorescence
microscopy analysis (Figure 6A).
To further assess the neuroprotective effect of 1A9 or
2C3 immunotherapy, Fluoro-Jade B (FJB) binding assay,
which specifically detects degenerative neurons, [29],
was performed. As depicted in Figure 6B, abundant FJB-
positive neurodegenerative neurons were evident in
untreated Tg2576 mouse brains. In contrast, such neuro-
degenerative neurons were negligible in 1A9- (Figure 6B)
or 2C3-treated Tg2576 mouse brains (Figure 6B), indicat-
ing that 1A9 or 2C3 immunotherapy protects Tg2576
mice from neuronal degeneration.
Double-labeling analysis of AD brains (Figure 6C)
revealed that 1A9- or 2C3-positive neurons were degener-
ated as proven by Fluoro-Jade B(FJB) binding, indicating
that the accumulation of intraneuronal AbOs is closely
associated with neuronal degeneration (Figure 6C).
Monoclonal 1A9 or 2C3 immunotherapy protects Tg2576
from the accumulation of AbOs
w?>To gain further insight into the neurotoxic action
of AbOs, we determined whether 1A9 and 2C3 immu-
notherapies targeting endogenous AbOs can prevent
the accumulation of extracellular or intracellular AbOs
in vivo. A11-dot immunoblot analysis revealed that
2C3 immunization had a significant preventive effect
(p < 0.05 versus untreated group, post-hoc test) on the
level of saline-soluble AbOs (Figure 7A) which repre-
sents extracellular soluble AbOs. In contrast, 2C3 and
1A9 immunizations resulted in a significant reduction
in the level of SDS-extractable AbOs (Figure 7B),
which represents mainly intracellular AbOs, owing to
the specificity of 1A9 or 2C3 towards intracellular Ab
assembly (see Figure 3). In the case of SDS-insoluble,
FA-extractable fractions which represent highly insolu-
ble AbOs, A11-dot immunoblot analysis showed that
2C3 immunization had a significant preventive effect
(p<0.001 versus untreated group, post-hoc test) (Figure
7C). In accordance with these data, double-labeling
analysis revealed that 1A9 and 2C3 immunotherapies
prevent the accumulation of A11-immunoreactive
granules in the neurons regardless of the abundant
A11-specific fluorescence found in untreated mice
(Figure 7D).
Discussion
The development of AbOs-selective antibodies has greatly
facilitated the understanding of in vivo relevance of endo-
genous AbOs-mediated synaptic failure or neuronal
degeneration. To prove this issue, a prophylactic study to
control endogenous AbOs using AbOs-selective antibo-
dies is required. Several conformation-dependent antibo-
dies such as oligomer- or fibril-specific antibodies were
reported previously [12,20,21,27,30,31], but none of them
was examined for this purpose. In the current study, we
successfully generated monoclonal oligomer-specific 1A9
and 2C3 using a novel design concept. Monoclonal 1A9
recognizes HMW-oligomers (100~230-mers), whereas
2C3 recognizes LMW- and HMW-oligomers ranging in
sizes larger than pentamers (5~230-mers). In support of a
previous report [12], prefibrillar oligomer-selective A11
appears to be specific to HMW-oligomers. Under condi-
tions of SDS-PAGE, 1A9-, 2C3-, or A11-oligomeric con-
formers were consistently detected at 70-180 kDa
corresponding to 15~40-mers. Note that neither 1A9 nor
2C3 reacted with monomers and fibrils. In spite of hetero-
geneity in size, AFM clearly demonstrated that the toxic
1A9-, 2C3-, or A11-oligomeric conformers display rela-
tively compact spherical particles, not fibrilar structure.
Using these oligomer-selective 1A9 and 2C3, we found
that the majority of AbOs exclusively accumulated in
neurons, whereas the degree of staining of diffuse plaques
varied among antibodies tested (1A9>2C3 = A11). Under
our conditions tested, A11-immunoreactivity is occasion-
ally found in small diffuse plaques, in contrast with the
finding of a previous report [12]. These findings are
direct evidence that heterogeneous oligomeric confor-
mers exist as a distinct entity in both extracellular and
intraneuronal deposits in human brains. Furthermore,
the change of nuclear appearance in AbOs-burned neu-
rons is highly indicative of impending neuronal degenera-
tion: 1A9-positive AbOs may be associated with the most
severe neuronal degeneration among the three anti-oligo-
mer-specific antibodies tested. FJB binding assay, which
specifically detects degernerating neurons [29], also con-
firmed that 1A9- or 2C3-burned neurons in AD brains
were unequivocally FJB-positive, indicating that intra-
neuronal accumulation of AbOs is closely associated with
neuronal degeneration.
Using above-mentioned 1A9 and 2C3, we evaluated
whether a specific control of endogenous, extracellular
AbOs in vivo would be sufficient to prevent the disrup-
tion of neuronal function leading to memory loss. Our
in vivo investigation demonstrated that immunized sub-
jects have less intraneuronal accumulation of AbOs and
fewer degenerating neurons than untreated controls. In
addition, 2C3 and 1A9 protected Tg2576 mice from
postsynaptic degeneration and from the degeneration of
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Page 9 of 16Figure 6 Passive immunization protects Tg2576 mice from synaptic or neuronal degeneration.( A) Saline-insoluble, SDS-extractable
synaptic proteins were examined by Western blot analysis and probed for PSD95 (1:250), drebrin (DB, 1:100), and synaptophysin (SYP, 1:2000).
The p value was determined by one-way ANOVA: *p < 0.05. Representive Confocal immunofluorescence microscopy images of Tg2576 mouse
brain. Sections of the cortex of the untreated (PBS)-, 1A9-treated, or 2C3-treatedTg2576 mouse brain were immunostained with PSD-95 (Upper
part of panel A), Derbrin (DB, Middle part of panel A), synaptophysin (SYP, Lower part of panel A). Scale bar = 30 μm. (B) Confocal
immunofluorescence microscopy images of Tg2576 mouse brain. Sections of the hippocampus of the untreated (PBS)-, 1A9-treated, or 2C3-
treatedTg2576 mouse brain were immunostained with Fluoro Jade B (1:50000). Scale bar = 100 μm. (C) Representive Confocal
immunofluorescence microscopy images of AD brain. Sections of the hippocampus of AD brains were immunostained with Fluoro Jade B. Scale
bar = 20 μm.
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Figure 7 Passive immunization protects Tg2576 mice from accumulation of intraneuronal AbOs. Dot blot immunoassay for A11-
immunoreactive AbOs in saline-soluble extracts (A), saline-insoluble, SDS-extractable extracts (B), and SDS-insoluble, FA-extractable extracts (C)
obtained from untreated, 1A9-treated, or 2C3-treated mice (30 μg of total extracted brain protein per dot). Results from densitometric imaging
of these same samples. The line indicates the mean of each set. The p value was determined by one-way ANOVA: *p < 0.05, **p < 0.001. (C)
Confocal immunofluorescence microscopy images of Tg2576 mouse brain. Sections of the hippocampus of the Tg2576 mouse brain were
doubly immunostained with 7-AAD (red, 1:50) and anti-A11 antibody (green, 1:250). Scale bar = 10 μm.
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Page 11 of 16dendritic spines, respectively. These results place both
extracellular [22,32] and intraneuronal AbOs [33,34]
centrally within the mechanisms mediating AbO-
induced neuronal dysfunction leading to memory loss
[26,27]. In support of these data, our in vivo investiga-
tions clearly demonstrated that 1A9- and 2C3-treated
Tg2576 mice aged 13 months showed cognitive perfor-
mance superior to that of untreated Tg2576 mice, and,
ultimately, performed better than and/or as well as
untreated wild-type mice. It is unlikely that the impaired
performance of Tg2576 mice in learning and memory
t e s t si sd u et oc h a n g e si nm o t i v a t i o no rs e n s o r ym o t o r
function, because the purpose of each behavioral test is
different, and different skills are required for a good per-
formance in each test. There were no differences in
locomotor activity and the total time spent exploring
objects in the novel object test between the wild-type
and Tg2576 mice. Thus, it is likely that endogenous oli-
gomeric 1A9- or 2C3-conformer is not only generated
in Tg2576 mice, but is also actually a bioactive molecule
in vivo, and its selective immunoneutralization by sys-
temic administration of 1A9 or 2C3 is sufficient to pre-
vent either short-term or long-term memory loss. This
in vivo neuroprotective activity of 1A9 appeared to be
superior to that of 2C3, supporting our current finding
that neuronal degeneration in AD brains is more severe
in 1A9-burned neurons than in 2C3-burned neurons.
Recently, the generation of a new mouse model expres-
sing only AbOs in neurons has demonstrated that endo-
genous AbOs are neurotoxic in vivo inducing synaptic
alteration, abnormal tau phosphorylation, glial activa-
tion, and neuronal loss [35], supporting the pathological
relevance of AbOs as shown herein. Taken together, the
results from this study indicate that both extracellular
and intraneuronal AbOs represent a molecular basis of
memory loss in vivo. Additional studies that attempt to
identify the cellular and molecular targets on the cellular
surface with which 1A9 or 2C3 interacts may yield
insights into the mechanisms underlying the synapto-
toxic or neurotoxic effects of AbOs or synaptoprotective
or neuroprotective effect of 1A9 or 2C3.
Conclusions
We herein performed a hypothesis-driven, proof of con-
cept study to prove the relevance of the in vivo Ab oli-
gomer hypothesis using monoclonal antibodies specific
to AbOs generated using a novel design method. We
found that AbOs are not only the real memory-relevant
molecules, but also the real culprits of neuronal degen-
eration. Now, we have evidence that AbOs are among
the earliest manifestation of the AD toxic process in
mice and humans. We are certain that our studies move
us closer to our goal of finding a therapeutic target and/
or confirming the relevance of our therapeutic strategy.
Methods
Generation of monoclonal 1A9 and 2C3
Synthetic Ab1-42 (r-peptide, Osaka, Japan) was dis-
solved in distilled, deionized H2O, or 10 mM phosphate
buffer at 250 μM, and allowed to incubate at 37°C for
18 h. Twenty microgram of preincubated Ab1-42 was
separated by NuPAGE 4-12% Bis-tris glycine gels, fol-
lowed by CBB staining. Balb-c mice were immunized by
injection with 2.5 μgo fA b1-42 tetramer alone, which
was excised from the gel and emulsified with complete
Freund’s adjuvant, into foot pads, followed by six addi-
tional injections. Inguinal lymphonode was used to gen-
erate hybridomas by fusion with Sp2/O-Ag14 myeloma
cells with polyethylene glycol 1500. Initial screening was
performed by dot blot analysis, applying 2.5 μl of seed-
free fresh or 18-h preincubated Ab1-42 (2.5 ng/dot) to a
nitrocellulose membrane [22]. The blots were then
allowed to dry and blocked with 5% low-fat milk and
1% BSA in PBS containing 0.05% Tween-20 (PBST) and
incubated with culture medium supernatant, followed by
horseradish peroxidase (HRP)-labeled goat anti-mouse
or anti-rabbit F(ab’)2 antibody (1:3000; Amersham). Dot
immunoblots were visualized with an ECL kit using
LAS3000 mini (Fujitsu, Tokyo, Japan).
Preparation of Ab1-42 peptide
Synthetic Ab1-42 was dissolved in 0.02% ammonia solu-
tion at 250 μM. To obtain seed-free Ab42 solutions
(540,000 g sup), the prepared solutions were centrifuged at
540,000 g for 3 h using an Optima TL ultracentrifuge
(Beckman, USA) to remove undissolved peptides, which
can act as preexisting seeds. The supernatant was collected
and stored in aliquots at -80°C until use. Immediately
before use, the aliquots were thawed and diluted with TBS
(150 mM NaCl and 10 mM Tris-HCl, pH 7.4). For time-
course experiments, 540,000 g sup was incubated for an
indicated time (0-72 h), and soluble AbOs were retained
after 100,000 g ultracentrifugation for 1 h, followed by dot
immunoblot analysis (2.5 ng/dot) [22]. Because the 4-h-
incubated mixture is suitable for the characterization of
soluble AbO standards, we used it in further experiment
instead of the 18-h-incubated mixture used in the first
screening. To further assess whether monoclonal 1A9 or
2C3 recognizes Ab fibrils, seed-free Ab42 solutions (25
μM) were incubated for 5 days at room temperature. Elec-
tron-microscopy-confirmed Ab fibrils were subjected to
dot immunoblot analysis (2.5 ng/dot) [22].
Electron microscopy (EM)
For electron microscopy, samples were diluted with dis-
tilled water and spread on carbon-coated grids. The grids
were negatively stained with 1% phosphotungstic acid and
examined under a Hitachi H-7000 electron microscope
(Tokyo, Japan) with an acceleration voltage of 77 kV.
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BN-PAGE analysis was performed following the manu-
facture’s instruction (Invitrogen, Carlsbad, CA): 4%, 6%,
8%, 10%, 12%, 14%, 16%, 18%, 20%, and 4-16% Novex
®
Bis-Tris gel was used. The apparent molecular masses of
LMW-oligomers were calculated from the Ferguson plots
with known molecular mass standards (a-lactalbumin,
14.2 kDa; carbonic anhydrase, 29 kDa; chickin egg albu-
min, 45 kDa; bovine serum albumin, 66 kDa monomer,
and 132 kDa dimer; urease, 272 kDa monomer and
545 kDa dimer) (Sigma). For two-dimensional native/
SDS-PAGE, one lane was excised from the gel and
applied directly for SDS-PAGE. Immunoblot analysis was
performed as described previously [36].
Ab-induced toxicity assay
We conducted the Ab-induced toxicity assay according
to previously published methods [22]. Briefly, rat pheo-
chromocytoma 12 (PC12) cells were cultured in DMEM
(Invitrogen, Carlsbad, CA) supplemented with 10% heat-
inactivated horse serum (Invitrogen) and 5% FBS (Invi-
trogen). For their differentiation, PC12 cells were plated
on 10-cm
2 poly-L-lysine-coated (10 mg/ml) dishes at a
density of 20,000 cells/cm
2 a n dc u l t u r e df o r6d a y si n
DMEM supplemented with 100 ng/ml nerve growth fac-
tor (NGF; Alomone Labs, Jerusalem, Israel) (PC12N).
Basically, toxicity was assessed using different Ab con-
formers: seed-free Ab1-42 vs. 2-h- or 4-h-preincubated
Ab1-42 with or without 540,000 g ultracentrifugation
for 1 h. PC12N was exposed to seed-free or preincu-
bated Ab1-42 at 25 μM for 48 h at 4°C. Toxicity was
assessed by Live/Dead two-color fluorescence assay
(Molecular Probes, Eugene, OR) or CytoTox 96 Non-
Radioactive Cytotoxicity Assay Kit (Promega, Madison,
DI) in accordance with the manufacturer’s instructions
as described previously [22].
Ultrafiltration and molecular sieving (UF/MS)
To characterize the size of de novo formed toxic AbOs
at 25 μM, serial ultrafiltration using Microcon
® 3-, 10-,
30-, and 10-kDa cut-off membranes (Millipore Corp.
Billerica, MA) was performed to prepare four filtrates
(12,000 g-centrifuge for 90 min, Fr. 1, >3 kDa; 12,000 g-
centrifuge for 60 min, Fr. 2, 3-10 kDa; 12,000 g-centri-
fuge for 30 min, Fr. 3, 10-30 kDa; 12,000 g-centrifuge
for 15 min, Fr. 4, 30-100 kDa) and one retentate (Fr. 5,
>100 kDa). Each fraction at 25 μM was subjected to Ab-
induced toxicity assay as described above. PC12N cells
were exposed to each fraction and the toxic fraction was
assessed as described above. The distribution of the
A11, 1A9, 2C3, or 4G8 conformer was characterized by
dot blot analysis as described above. To determine the
morphology of toxic oligomers, each fraction was also
subjected to atomic force microscopy (AFM).
Atomic force microscopy (AFM)
AFM assessment was performed as reported previously
[25]. Briefly, samples were dropped onto freshly cleaved
mica. After allowing them to stand for 1 h, following
by washing with water, the samples were assessed in a
solution using a Nanoscope IIIa (Digital Instruments,
Santa Barbara, CA, USA) set at tapping mode. OMCL-
TR400PSA (Olympus, Japan) was used as a cantilever.
Consecutive scans were monitored until distortion due to
creep or shifts in the slow scan direction were negligible
before collecting scans at sizes of 2 μm with the maximum
512 × 512 pixel resolution.
Immunohistochemistry
The left hemispheres of the brains of Tg2576 mice were
sagitally cut into 30-μm-thick sections using a freezing
microtome (RM 2145; Leika, Wetzlar, Germany). The
tissue blocks from human subjects (4 AD subjects and 3
normal controls) or mice were fixed in 4% paraformal-
dehyde with 0.1 M phosphate-buffered saline (pH 7.6)
and embedded in paraffin wax. After deparaffinization,
heat-induced antigen retrieval was achieved by boiling
sections for 10 min in a microwave oven in 0.01 M
citrate buffer pH6.0, followed by 3 min incubation in
99% formic acid and then blocking of endogenous per-
oxidase. Then sections were subsequently incubated for
1 hour with primary antibody diluted in blocking buffer
with normal goat or horse serum (2%), and after wash-
ing for 1 hour, with a secondary antibody in the same
buffer. All incubations were done in parallel and photo-
graph exposures were equal for sections in human and
mice.
The following primary antibodies were used: mono-
clonal antibodies 6E10 and 4G8 against human Ab
sequence corresponding to residues 1-16 and 17-24,
respectively, (Covance Immuno-Technologies, Dedham,
MA), Polyclonal A11 specific to AbOs (Biosource,
Camarillo, CA), anti-SYP (D4) antibody, monoclonal
antibody against b-actin (C4) (Santa Cruz, Santa Cruz,
CA), monoclonal anti-drebrin antibody (MBL, Nagoya,
Japan), polyclonal anti-PSD-95 (CT) antibody (Invitro-
gen, Camarillo, CA), and our monoclonal 1A9 and 2C3
antibodies specific to AbOs.
T h ef o l l o w i n gs e c o n d a r ya n t i b o d i e sw e r eu s e d
(1:1000): Goat anti-rabbit or anti-mouse IgG conjugated
with horse-radish peroxidase (HRP) (Invitorogen, Carls-
bad, CA), and Goat anti-mouse IgG conjugated with
Alex Fluor (AF) 488 or 594 and goat anti-rat IgG conju-
gated with AF 488 (Molecular Probes, Eugene, OR).
Immunopositive signals were visualized using an obser-
vation system (Compix Imaging System, Lake Oswego,
OR) linked to an Olympus microscope BX50 through a
highly sensitive CCD camera or a confocal laser scan-
ning microscope (Carl Zeiss LSM510).
Takamura et al. Molecular Neurodegeneration 2011, 6:20
http://www.molecularneurodegeneration.com/content/6/1/20
Page 13 of 16Fluoro-Jade B was purchased from Chemicon (now
part of Millipore, Schwalbach, Germany). 7-AAD was
purchased from Invitrogen (Carlsbad, CA).
Histochemistry
For Fluoro-Jade B histochemistry (1:50000), 5-μm-thick
paraffin-embedded sections were deparafinized and
stained following the manufacturer’s instruction (Chemi-
con, now part of Millipore, Schwalbach, Germany). The
Fluoro-Jade B-stained product fluoresces when exited at
488 nm and staining was imaged using a confocal laser
scanning microscope (Carl Zeiss LSM510). The same
procedure was applied for 30-μm-thick cryostat sections.
Cell culture and cellular uptake
Human neuroblastoma SH-SY5Y (SY5Y) cells were cul-
tured in Dulbecco’s modified Eagle’s medium/Ham’s F-12
medium supplemented with 10% fetal bovine serum. To
investigate the fate of extracellular Ab,S Y 5 Yc e l l sw e r e
exposed to HiLyte Fluor™488-labeled AbMs (10 kDa-
filtrate), HiLyte Fluor™488-labeled AbOs (30 kDa-
retentate) at 5 μM (AnaSpec, San Jose, CA), or Fluor™488
alone for 10 min, 30 min, and 180 min. In a separate set of
experiment, cultures were treated at 37°C for 0, 3, 6, and
2 4hw i t h5μMF l u o r ™488-labeled AbOs, and for 24 h
with 5 μM Fluor™488-labeled AbMs and synthetic Ab42-
1 (AnaSpec, San Jose, CA). Toxicity was assessed by
CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit in
accordance with the manufacturer’s instructions (Pro-
mega, Madison, DI) as described previously [22].
Protein extraction and immunoblotting
Saline-soluble, saline-insoluble, SDS-soluble fractions, or
SDS-insoluble, formic acid (FA)-extractable fractions were
prepared from the Tg2576 mouse brains as described pre-
viously [32]. Briefly, frozen brain samples were homoge-
nized with a motor-driven Teflon/glass homogenizer
(20 strokes) in TBS containing a cocktail of protease inhi-
bitors (150 mg/ml), followed by centrifugation at 100,000
g for 1 h. The resultant supernatant (soluble fraction) was
subjected to dot blot immunoanalysis or western blotting
employing the same antibodies as those used for immuno-
histochemical staining. The pellet was further extracted
with 2% sodium dodecylsulphate (SDS), followed by 70%
FA, and the homogenate was ultracentrifuged as described
above. The resultant supernatant (insoluble fraction) was
also subjected to dot blot immunoanalysis and western
blot analysis. For western blotting, aliquots of isolated frac-
tions were separated using NuPAGE 4-12% bis-tris-glycine
gels and transblotted to nitrocellulose membrane or
Immobilon P (Millipore) for 1 h at 400 mA using 10 mM
3-cyclohexylamino-1-propancsulphonic acid (pH 11) con-
taining 10% methanol. Membranes were blocked for 3 h at
room temperature with 5% low-fat milk and 1% BSA in
PBST and incubated with either the polyclonal anti-A11
(1:1000) or anti-PSD95 antibody (1:250), and monoclonal
anti-drebrin (1:100), anti-SYP (1:2000), and anti-b actin
antibodies (1:1000), followed by HRP-labeled goat anti-
rabbit or anti-mouse F(ab’)2 antibody (1:3000; Amersham).
I m m u n o b l o t sw e r ev i s u a l i z e dw i t ha nE C Lk i tu s i n g
LAS3000 mini (Fujitsu, Tokyo, Japan). Densitometric ana-
lysis of immunoblot was performed using Multi Gauge
v3.0 software (Fuji Film, Tokyo), and bands of interest
were normalized to the corresponding actin bands
indicated.
Immunization and behavioral analyses
All animal procedures were performed in accordance with
a protocol approved by the Animal Care Committee of
the National Institute for Longevity Sciences. Several
3-month-old female nontransgenic (non-Tg) and Tg2576
mice that carry and overexpress the human APP gene
with the Swedish double mutation (K670N; M671L) of
familial AD were purchased from Taconics (Germantown,
NY, USA) and maintained at our animal care facility until
13 months of age. To determine whether immunization
prevents the development of Alzheimer-like phenotype,
4-month-old Tg2576 mice were administered 1A9 or 2C3
(0.4 mg/kg/week), or PBS intravenously via the tail vein
until 13 months of age. Memory functions were measured
at 13 months of age in the following four behavioral para-
digms, as described previously [28]: (1) spontaneous alter-
nation in the Y-maze test; (2) novel object recognition
test; (3) Morris water maze test; and (4) cued and fear con-
ditioning tests. Mice were sacrificed 3 days after the termi-
nation of the behavioral tests for biochemical and
histological assessments. Experimental results were ana-
lyzed by one-way ANOVA and two-way ANOVA, with
Fisher’s test for post hoc analysis.
Spontaneous alternation in Y-maze test
The maze was made of black painted wood; each arm
was 40 cm long, 12 cm high, 3 cm wide at the bottom,
and 10 cm wide at the top. The arms converged at an
equilateral triangular central area that was 4 cm long at
its longest axis. Each mouse was placed at the center of
the apparatus, the sequence and number of arm entries
were recorded for each mouse over an 8 min period.
Alternation was defined as successive entry into the three
arms on overlapping triplet sets. Alternation behavior (%)
was calculated as the ratio of actual alternations to possi-
ble alternations (defined as the number of arm entries
minus two) multiplied by 100.
Novel object recognition test
The test procedure consisted of three sessions: habitua-
tion, training, and retention. Each mouse was habituated
to the box (30 × 30 × 35 cm), with 10 min of exploration
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During the training session, two objects were placed at
the back corner of the box. A mouse was then placed
midway at the front of the box and the total time spent
exploring the two objects was recorded for 10 min. Dur-
ing the retention session, the mice were placed back in
the same box 24 hr after the training session, in which
one of the familiar objects used during the training was
replaced with a novel object. The animals were then
allowed to explore freely for 10 min, and the time spent
exploring each object was recorded. Throughout the
experiments, the objects used were counterbalanced in
terms of their physical complexity and emotional neutral-
ity. A preference index, a ratio of the amount of time
spent exploring any one of the two objects (training ses-
sion) or the novel object (retention session) over the total
time spent exploring both objects, was used to measure
cognitive function. To eliminate the influence of the last
behavioral test, the objects were changed each time.
Morris water maze test
The Morris water maze test was conducted in a circular
pool (120 cm in diameter) filled with water at a tem-
perature of 22 ± 1°C. A hidden platform (one block)
(7 cm in diameter) was used. The mice underwent two
trials (one block) for 10 consecutive days, during which
the platform was left in the same position. The distance
taken to locate the escape platform was determined in
each trial using the Etho Vision system (Neuroscience
Idea Co., Ltd., Osaka, Japan).
Cued and contextual fear conditioning tests
For measuring basal levels of freezing response (precon-
ditioning phase), mice were individually placed in the
conditioning cage (17 × 27 × 12.5 cm) for 1 min, then in
the conditioning cage (25 × 31 × 11 cm) for 2 min. For
training (conditioning phase), mice were placed in the
conditioning cage, then a 15 sec tone (80 dB) was deliv-
ered as a conditioned stimulus. During the last 5 sec, an
unconditioned stimulus was applied through a shock
generator (Neuroscience Idea Co., Ltd.). This procedure
was repeated 4 times at 15 sec intervals. Cued and con-
textual tests were carried out 1 day after the fear condi-
tioning. For the cued test, the freezing response was
measured in the neutral cage for 1 min in the presence of
a continuous-tone stimulus identical to the conditioned
stimulus. For the contextual test, mice were placed in the
conditioning cage and the freezing response was mea-
sured for 2 min in the absence of the conditioned
stimulus.
Ethics Statement
The research protocol was approved by the local animal
esthetics committees at Research Institute, National
Center for Geriatrics and Gerontology (Animal Care
Committee) prior to initiation of the study. The research
project was approved by the local ethics committee of
Hirosaki University Graduate School of Medicine, and
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Statistical analyses
We used factorial design analysis of variaence (ANOVA)
or Mann-Whitney test to analyze data as appropriate.
Significant ANOVA values were subsequently subjected
to simple main effects analyses or post hoc comparisons
of individual means using the Tukey’s or Dannett’s
method as appropriate. We considered p values of 0.05
as significant for all studies. Some of the data obtained
from animal experiments were analyzed by two-way
ANOVA, with Fisher’s test for post hoc analysis.
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